Engineers Gate Manager LP lifted its stake in MEDNAX Inc (NYSE:MD) by 315.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 71,236 shares of the company’s stock after buying an additional 54,077 shares during the period. Engineers Gate Manager LP’s holdings in MEDNAX were worth $3,083,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Summit Trail Advisors LLC grew its position in shares of MEDNAX by 2,817.3% in the 1st quarter. Summit Trail Advisors LLC now owns 103,564 shares of the company’s stock valued at $104,000 after buying an additional 100,014 shares during the last quarter. Sandy Spring Bank purchased a new position in shares of MEDNAX in the 1st quarter valued at $176,000. Blair William & Co. IL purchased a new position in shares of MEDNAX in the 1st quarter valued at $211,000. Macquarie Group Ltd. grew its position in shares of MEDNAX by 36.1% in the 4th quarter. Macquarie Group Ltd. now owns 4,900 shares of the company’s stock valued at $262,000 after buying an additional 1,300 shares during the last quarter. Finally, Unison Advisors LLC purchased a new position in shares of MEDNAX in the 2nd quarter valued at $274,000. 95.63% of the stock is currently owned by hedge funds and other institutional investors.

In other news, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction on Tuesday, May 22nd. The shares were sold at an average price of $46.43, for a total value of $139,290.00. Following the completion of the sale, the insider now owns 39,716 shares in the company, valued at approximately $1,844,013.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Dominic J. Andreano sold 18,000 shares of the firm’s stock in a transaction on Monday, June 11th. The stock was sold at an average price of $46.95, for a total transaction of $845,100.00. Following the completion of the sale, the senior vice president now owns 24,896 shares of the company’s stock, valued at approximately $1,168,867.20. The disclosure for this sale can be found here. Insiders sold a total of 75,251 shares of company stock valued at $3,462,384 in the last 90 days. Company insiders own 2.40% of the company’s stock.

Several research analysts have issued reports on the stock. Leerink Swann assumed coverage on shares of MEDNAX in a research report on Thursday, July 12th. They set a “market perform” rating and a $50.00 price objective on the stock. TheStreet downgraded shares of MEDNAX from a “b” rating to a “c” rating in a research report on Monday, April 23rd. Zacks Investment Research raised shares of MEDNAX from a “sell” rating to a “hold” rating in a research report on Tuesday. ValuEngine raised shares of MEDNAX from a “strong sell” rating to a “sell” rating in a research report on Friday, August 3rd. Finally, Credit Suisse Group lowered their price objective on shares of MEDNAX to $57.00 and set a “neutral” rating on the stock in a research report on Monday, May 7th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $54.71.

Shares of MEDNAX stock opened at $47.74 on Friday. MEDNAX Inc has a 1 year low of $40.56 and a 1 year high of $63.04. The company has a current ratio of 1.52, a quick ratio of 1.52 and a debt-to-equity ratio of 0.59. The firm has a market cap of $4.43 billion, a price-to-earnings ratio of 13.77, a price-to-earnings-growth ratio of 1.26 and a beta of 0.19.

MEDNAX (NYSE:MD) last issued its quarterly earnings data on Thursday, August 2nd. The company reported $1.07 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.07. MEDNAX had a net margin of 9.59% and a return on equity of 10.42%. The company had revenue of $915.90 million for the quarter, compared to the consensus estimate of $911.77 million. During the same period last year, the firm posted $0.85 EPS. MEDNAX’s revenue for the quarter was up 8.6% on a year-over-year basis. research analysts forecast that MEDNAX Inc will post 3.76 EPS for the current year.

About MEDNAX

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.

Featured Article: What are the Different Types of Leveraged Buyouts?

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.